GE 137

Drug Profile

GE 137

Alternative Names: GE137

Latest Information Update: 07 Dec 2015

Price : $50

At a glance

  • Originator GE Healthcare
  • Class Imaging agents; Peptides
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Breast cancer; Orofacial cancer

Most Recent Events

  • 03 Dec 2015 Clinical trials in Orofacial cancer in United Kingdom (Parenteral)
  • 03 Dec 2015 Clinical trials in Breast cancer in United Kingdom (Parenteral)
  • 12 Aug 2015 Guy's and St. Thomas' NHS Foundation trust plans a pilot trial for Breast cancer and orofacial cancer in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top